Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trastuzumab in early-stage breast cancer: the question of treatment timing.

Literature DB >> 18793028

Trastuzumab in early-stage breast cancer: the question of treatment timing.

Steven Simoens¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2008 PMID： 18793028 DOI： 10.2165/00019053-200826100-00001

Source DB: PubMed Journal: Pharmacoeconomics ISSN： 1170-7690 Impact factor: 4.981

× No keyword cloud information.

12 in total

1. Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.

Authors: Steven Simoens
Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.981

2. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal: Lancet Date: 2007-01-06 Impact factor: 79.321

3. Alchemy, the safer cigarette, and Philip Morris.

Authors: Alan Blum
Journal: Lancet Date: 2008-05-17 Impact factor: 79.321

4. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Authors: Elizabeth Tan-Chiu; Greg Yothers; Edward Romond; Charles E Geyer; Michael Ewer; Deborah Keefe; Richard P Shannon; Sandra M Swain; Ann Brown; Louis Fehrenbacher; Victor G Vogel; Thomas E Seay; Priya Rastogi; Eleftherios P Mamounas; Norman Wolmark; John Bryant
Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544

5. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245

6. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.

Authors: K J Dedes; T D Szucs; P Imesch; A Fedier; M K Fehr; D Fink
Journal: Ann Oncol Date: 2007-09 Impact factor: 32.976

Trastuzumab in early-stage breast cancer: the question of treatment timing.

1. Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.

2. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

3. Alchemy, the safer cigarette, and Philip Morris.

4. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

5. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

6. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.

7. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.

8. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.

Review 9. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.

Review 10. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer.

1. Funding a clinical trial: the perspective of a medicines funder.